DrugDashboards

Caverject

Alprostadil · ALPROSTADIL 20.5 ug/mL · Injection, Powder, Lyophilized, For Solution · Intracavernous · Pharmacia & Upjohn Company LLC

NDC 00009-3701-05 · 6 VIAL, SINGLE-DOSE in 1 PACKAGE / 1 mL in 1 VIAL, SINGLE-DOSE · NDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price is up 20% over the past year, to $95.72 per unit. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$50.00$100.00Jul 2013Jan 2018$95.72
11 price points · per · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$630.08
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$331
326 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for alprostadil (injectable) in the next 90 days

sterile injectable · sole-source market · price up 5% YoY

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA020379
TE code
AP
Approval date
Jul 6, 1995
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Alprostadil (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Endo USA, Inc.ALPROSTADIL 20 ug/mLJul 15, 2026Sep 2, 2026
Endo USA, Inc.ALPROSTADIL 10 ug/mLJul 15, 2026Sep 2, 2026
Endo USA, Inc.ALPROSTADIL 40 ug/mLJul 15, 2026Sep 2, 2026
Pharmacia & Upjohn Company LLCALPROSTADIL 10 ug/.5mLJul 15, 2026Sep 2, 2026
Pharmacia & Upjohn Company LLCALPROSTADIL 20.5 ug/mLJul 15, 2026Sep 2, 2026
Pharmacia & Upjohn Company LLCALPROSTADIL 41.1 ug/mLJul 15, 2026Sep 2, 2026
Pharmacia & Upjohn Company LLCALPROSTADIL 20 ug/.5mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Caverject — NDC 00009-3701-05," retrieved September 3, 2026, https://drugdashboards.com/drug/00009370105.

Free to cite with attribution — see how the data is put together.